Researchers have developed a new bioinformatics pipeline that could help investigate the mechanism underlying the development of autoimmune diseases following SARS-CoV-2 infection.
List view / Grid view
Sartorius Launches the Octet® SF3 SPR System, Strengthening its Leadership in Advanced Label-Free Bioanalytics
Sartorius has launched a proprietary fluidic-free instrument platform for real-time, label-free analysis of biomolecular interactions.
Scientists have developed a deep learning-based model trained on drug-induced gene expression signatures to predict drug-drug interactions.
Using a machine learning model, scientists could predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to.
Tune in to this podcast to hear industry experts discuss cell line monoclonality and the emerging methods that can support clonal origin assurance.
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
Bulletin: Utilising the multiparameter capability of the Ze5 Cell Analyser to monitor T cell exhaustion and effects of immunotherapy
Read this bulletin to learn about a Bio-Rad study where they developed and tested a 16-parameter flow cytometry panel applicable to the interrogation of a range of biologically relevant markers of T cell activation.
Improving processes in the lab can enable researchers to spend their time on other tasks and increase the accuracy of their findings, including when imaging. In this Q&A, Dr Hari Shroff from the US National Institutes of Health (NIH) discusses his recent study, published in Nature where confocal microscopy was…
This article explores the current state of artificial intelligence (AI) in drug discovery and development, discussing the obstacles holding back wider adoption. Dr Mark Eller, Senior Vice President of Research and Development at Aria Pharmaceuticals, makes the case that to succeed, AI must be integrated as a partner alongside core…
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
Scientists have created a pipeline for identifying, prioritising and evaluating potential tumour antigens for personalised cancer vaccines.
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
A new report says that the global lab automation market is set to grow significantly until 2031, due to advanced drug development.
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
A research team based at Skoltech in Russia has developed an artificial intelligence-driven solution for highly accurate detection of efficacious binding sites to expedite drug discovery.